CN106290823A - A kind of alzheimer syndrome mark ABCA7 detection kit and preparation method - Google Patents

A kind of alzheimer syndrome mark ABCA7 detection kit and preparation method Download PDF

Info

Publication number
CN106290823A
CN106290823A CN201610908404.XA CN201610908404A CN106290823A CN 106290823 A CN106290823 A CN 106290823A CN 201610908404 A CN201610908404 A CN 201610908404A CN 106290823 A CN106290823 A CN 106290823A
Authority
CN
China
Prior art keywords
abca7
preparation
detection kit
alzheimer syndrome
detection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201610908404.XA
Other languages
Chinese (zh)
Inventor
罗朝领
董敏
陈潇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SHANGHAI KAIJING BIOLOGICAL SCIENCE & TECHNOLOGY Co Ltd
Original Assignee
SHANGHAI KAIJING BIOLOGICAL SCIENCE & TECHNOLOGY Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SHANGHAI KAIJING BIOLOGICAL SCIENCE & TECHNOLOGY Co Ltd filed Critical SHANGHAI KAIJING BIOLOGICAL SCIENCE & TECHNOLOGY Co Ltd
Priority to CN201610908404.XA priority Critical patent/CN106290823A/en
Publication of CN106290823A publication Critical patent/CN106290823A/en
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/54346—Nanoparticles
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to a kind of alzheimer syndrome mark ABCA7 detection kit and preparation method.This test kit includes PVC base plate, fluorescence pad, nitrocellulose filter, sample pad and adsorptive pads；Described sample pad, nitrocellulose filter, fluorescence pad, adsorptive pads are fixed on PVC base plate by horizontal direction.Coated mouse-anti people's ABCA7 monoclonal antibody 1 nanometer fluorescent microspheres complex, chicken IgY nanometer fluorescent microspheres complex is had on described fluorescence pad；Detection line that mouse-anti people's ABCA7 monoclonal antibody 2 constitutes and the nature controlling line that rabbit anti-chicken IgY antibody is constituted is had on described nitrocellulose filter.The present invention utilizes nanometer fluorescent microspheres to detect ABCA7, its background value is low, the detection time is short, specificity and highly sensitive, testing result accurate, the generaI investigation for clinical diagnosis and alzheimer syndrome provides relatively reliable foundation.

Description

A kind of alzheimer syndrome mark ABCA7 detection kit and preparation method
Technical field
The present invention relates to a kind of alzheimer syndrome mark ABCA7 detection kit and preparation method, the present invention Belong to medical product field.
Background technology
Alzheimer syndrome (AD) is the nervous system degenerative disease of the Progressive symmetric erythrokeratodermia development of a kind of onset concealment.AD Being one of geratic period most common disease, the World Health Organization (WHO) estimates that the prevalence of whole world over-65s elderly population AD is 4%~7%.AD prevalence is closely related with the age, and the age the most often increases by 6.1 years old, and prevalence raises 1 times；Old age more than 85 years old In crowd, AD prevalence may be up to 20% ~ 30%.Calendar year 2001, whole world AD patient was more than 20,000,000, estimated that the year two thousand forty, whole world AD suffer from Person will be more than 80,000,000.From 1999, China initially entered aging society, corresponding, current Aged in China crowd The ill population of AD alreadys more than 6,000,000, it is contemplated that will be that the ill population of AD is the most in the world more than 20,000,000 to the year two thousand fifty ill population The country that many, growth rate is the fastest.AD is the most common disease causing old people to lose activity of daily living, is also to cause old age The 5th cause of disease that people is dead.AD not only brings huge misery to patient, returns family and society brings heavy spirit pressure Power and medical treatment, Burden of care.Therefore, AD has become the significant problem affecting global public health and social sustainable development.To the greatest extent Pipe countries in the world are a large amount of manpower and materials to the Innovation Input of AD medicine, still fail to develop and delay or stop AD to be in progress Medicine.Therefore early diagnosis treatment is the critical period of preventing and treating AD.
The diagnostic method that alzheimer syndrome clinic is conventional at present has: 1, neuroimaging inspection, electroencephalogram: such as meter Calculate hippocampus neurofibrillary tangles and senile plaque number, with the coincidence rate of clinical diagnosis up to 81%～88%.Due to Elderly people People also has a number of neurofibrillary tangles and senile plaque, and has same distribution, and accuracy rate is relatively low, and time-consuming expense High；2, Five neuropsychological tests: Five neuropsychological tests be modern psychology test on the basis of grow up for brain function One class psychometry method of assessment.Because individual variation is relatively big, accuracy rate is poor.For early stage patient, recall rate is unsatisfactory； 3, gene test: by detection alzheimer Comprehensive Criteria sex factor, such as amyloid precursor protein gene (APP), early Old element 1,2 genes (PS1, PS2) etc., have simplicity, sensitivity, the advantage such as special, but need to detect accordingly equipment, technology requirement Height, costly, it is difficult to promote.4, hematological examination, cerebrospinal fluid detection: mainly for detection of alzheimer syndrome specificity Albumen, finds the accompanying diseases that exists or the potential risk factor of complication, discovery.The most conventional ELISA immune diagnostic technique In detection serum or cerebrospinal fluid specific proteins, have conventional program tediously long time-consuming, be not easy to promote, sensitivity low etc..Therefore Find a kind of quickly, be convenient for carrying, simple to operate, highly sensitive, diagnosis and development of methodology to alzheimer syndrome Tool is of great significance.
Mankind's ABCA7 gene is positioned at 19p13.3, total length about 24kb, comprises 46 exons, coding adenosine triphosphate knot Close cassette transporter body (ATP binding cassette transporter, ABC)[1].ABC be distributed widely in eukaryote and A superfamily protein in prokaryote, most of ABC protein integration, on cell membrane or organelle film, are mainly responsible for material Transmembrane transport, especially play an important role in the reverse of cholesterol[2].ABCA7 is identified first is at human macrophage In[3].The ABCA7 albumen of people be one by the transporter that molecular mass is 235kDa of 2146 Amino acid profiles, be full molecule Transport protein, comprises and has cytoplasm ATP of 2 high conservatives and combine box and 2 membrane spaning domains[1].ABCA7 mainly expresses In periphery lymphocyte, thymus, spleen, bone marrow etc..Langmann etc.[4]Confirmed by Western blot and Reverse transcription-PCR analysis ABCA7 also has relatively high expressed in human brain.Kim etc.[5]In situ hybridization at adult rat discloses ABCA7 in cerebral tissue Expression is high, especially at neurons of hippocampus CA 1.Kim research in 2006 finds, ABCA7 mRNA is in microglia Expression is 10 times in neuron[6].Many research reports, ABCA7 is high expressed in central nervous system.
Austria Ullrich etc.[7]It was found that, hypercholesterolemia can increase AB peptide fragment (1 ~ 40) in Mice Body Generation and the phosphorylation of Protein tau, and the quantity of cholinergic neuron and function and ability of learning and memory are impacted. Recently, Woojins.Kim etc.[8]Research finds, knocks out ABCA7 gene in AD rat model, hippocampus A β plaque block precipitation in brain Add 53%.Hughes etc.[9]Research proves to find that ABCA7rs3764650 polymorphism is notable with A β plaque block by PET imaging Relevant.Relevant scholar also demonstrate that[10-13]The polymorphism of ABCA7rs3764650 is relevant to the generation of AD.Study discovery recently, There is also 3 loci polymorphisms, including rs11550680 [14]、rs3752246 [15], rs4147929[16]。
Karch etc.[17]Research display, ABCA7rs3764650 minimum gene C has with the process of AD age of onset and disease Closing, ABCA7 expression is relevant to the dull-witted order of severity, and the disappearance degree of the ABCA7 the highest cognition of expression is the most serious.Also Having research to confirm, ABCA7rs3764650 Yu APOE ε 4 is in language learning and memory, working memory, three cognition sides of immediate memory There is significant interaction relationship in face[18]。
In sum, ABCA7 can regulate the content of Membrane cholesterol in central nervous system as a kind of integral membrane protein With distribution, these are all necessary to the stable state maintaining intracellular cholesteryl, and the formation of cholesterol scalable A β.ABCA7 Also scalable APP process and suppression toxicity A β plaque block formation.Therefore the discovery of ABCA7 exploration pathogenetic to AD, medicine The research of thing and other therapeutic interventions is significant.Not yet have been reported that currently, with respect to the research of ABCA7 test kit.Lead to herein Cross and set up ABCA7 dry type immunofluorescence quantitative method detection kit, for the early diagnosis of Alzheimer syndrome.
Fluorescent microsphere nano-particle has tremendous potential in marker detection field.It has the following characteristics that 1, sensitivity High: not by extraneous ambient interferences；2, stability is high: avoid sample corrosion or the quenching phenomenon of self decay initiation；3, spirit Activity is high: can combine variation spectrum；4, safety is high: be all safe from harm for tester, detection sample and environment；5, side The simplest: sample directly can be detected, it is not necessary to special handling；6, above feature determines that it is applied in terms of biomarker Prospect is broader, especially at the other detection field of bed.By fluorescent microsphere nanoparticle label mouse-anti people's ABCA7 monoclonal anti Body, sets up a kind of alzheimer syndrome mark ABCA7 detection kit and preparation method has in Clinical detection field Important using value.
Summary of the invention
For with present on problem, the invention provides a kind of alzheimer syndrome mark ABCA7 detection examination Agent box and preparation method.The invention have the characteristics that and combine dry type immuno-fluorescence assay people ABCA7, by specific monoclonal antibody with In sample, ABCA7 antigen forms double-antibody sandwich structure, and its accuracy and specificity are higher；Dry type immunofluorescence is utilized to survey Fixed, its background value is low, measures convenient, accurate, simple to operate.
It is an object of the invention to provide a kind of alzheimer syndrome mark ABCA7 detection kit and preparation side Method.
Test kit of the present invention includes PVC base plate, fluorescence pad, nitrocellulose filter, sample pad and adsorptive pads；Described sample Product pad, nitrocellulose filter, fluorescence pad, adsorptive pads are fixed on PVC base plate by horizontal direction.On described fluorescence pad There are coated mouse-anti people's ABCA7 monoclonal antibody 1-fluorescent microsphere nano-particle complex, chicken IgY-fluorescent microsphere nano-particle Complex；Detection line that mouse-anti people's ABCA7 monoclonal antibody 2 constitutes and rabbit anti-chicken IgY is had to resist on described nitrocellulose filter The nature controlling line that body is constituted；Described nano-particle footpath is 100 ~ 200nm.
The technical scheme is that
1) preparation of nitrocellulose filter (NC film)-PVC base plate: nitrocellulose filter is cut into 25mm × 300mm, is attached to PVC On base plate.Mouse-anti people's ABCA7 monoclonal antibody 2 is rule on nitrocellulose filter and obtains detecting line；By anti-for rabbit chicken IgY at cellulose nitrate On element film, line obtains nature controlling line.Then nitrocellulose filter (NC film)-PVC base plate is placed in drying baker and is dried；
2) utilize nanometer fluorescent microspheres particle marker mouse-anti people's ABCA7 monoclonal antibody 1 and chicken IgY, save backup.
3) preparation of pad: pad is cut into 9mm × 300mm slice, by glimmering for mouse-anti people's ABCA7 monoclonal antibody 1- Light microsphere nano particle composites, chicken IgY-fluorescent microsphere nano-particle complex mix according to a certain percentage, and uniform spreading is at knot Close on pad, put into stove-drying.
4) sample pad: glass fibre membrane is cut into 17mm × 300mm slice.
5) absorption pad: absorbent paper is cut into 17mm × 300mm slice.
7) assemble: above-mentioned adsorptive pads, sample pad, fluorescence pad are attached on PVC base plate successively, the intermedium that will post The reagent strip of one fixed width it is cut into cutting machine.
Accompanying drawing explanation
Fig. 1 dry type Immunofluorescence test system structure schematic diagram, wherein 1 is sample pad；2 is fluorescence pad；3 is nitric acid Cellulose membrane；4 is adsorptive pads；5 is PVC base plate；6 is target antigen in sample；7 is that fluorescent microsphere labelling mouse-anti people ABCA7 is mono- Anti-1；8 is fluorescent microsphere labelling chicken IgY；9 is detection line: mouse-anti people's ABCA7 monoclonal antibody 2；10 is nature controlling line: rabbit anti-chicken IgY.
Detailed description of the invention
Embodiment 1 prepares the dry type immunofluorescent reagent box of the alzheimer syndrome ABCA7 of the present invention
Test kit of the present invention includes PVC base plate, fluorescence pad, nitrocellulose filter, sample pad and adsorptive pads；Described sample Pad, nitrocellulose filter, fluorescence pad, adsorptive pads are fixed on PVC base plate by horizontal direction.
One, the preparation of nitrocellulose filter (NC film)-PVC base plate
1, draw film: celluloid enzyme action is become 25mm × 300mm, be attached on PVC base plate.Anti-for rabbit chicken IgY PBS is diluted to Concentration is 1mg/ml, is coated liquid as C line；With PBS, mouse-anti people's ABCA7 monoclonal antibody 2 is diluted to concentration is 1mg/ml, as T line. By spray film instrument, T line is coated liquid and C line is coated liquid and rule on nitrocellulose filter and obtain detection line and nature controlling line, 37 degree Dry, i.e. can get monoclonal antibody and be coated test strip.
Two, the preparation of pad
1, traget antibody: nanometer fluorescent microspheres granule and mouse-anti people's ABCA7 monoclonal antibody coupling method are by nanometer fluorescent microspheres Aldehyde radical be condensed by schiff base base under mild alkaline conditions with the amino on antibody protein, formed nanometer fluorescent microspheres-CH- NH2-ABCA7 antibody complex；The same manner forms nanometer fluorescent microspheres-CH-NH2-chicken IgY antibody complex.Fluorescent microsphere Nano-particle and mouse-anti people's ABCA7 monoclonal antibody or chicken IgY are according to 1:1(ul:ug) hybrid reaction 2h, prepare mouse-anti people ABCA7 Monoclonal antibody 1-fluorescent microsphere nano-complex or chicken IgY-fluorescent microsphere nano-particle complex.
2, the preparation of pad: pad is cut into 9mm × 300mm slice, by glimmering for mouse-anti people's ABCA7 monoclonal antibody 1- Light microsphere nano particle composites or chicken IgY-fluorescent microsphere nano-particle complex mix homogeneously according to a certain percentage are layered on knot Close on pad, put into and toast 2h under 37 degree of baking oven.
Three, prepared by other auxiliary materials
1, glass fibre membrane is cut into 17mm × 300mm slice.
2, absorption pad: absorbent paper is cut into 17mm × 300mm slice.
Four, assemble
Assemble test strips: paste on PVC base plate successively by nitrocellulose filter, absorbent paper, fluorescence pad, sample pad, use Cutting machine is cut into the reagent strip of one fixed width.
The using method of embodiment 2 test kit of the present invention
1, with pipettor pipette 50ul serum, blood plasma, CSF sample are added on the sample-adding pad of test strips；
2, room temperature stands 10min；
3,10min terminates, and test strips is put into reading data in immunofluorescence quantitative analysis instrument；
4, optical signalling is measured and analyzes and processes by immunofluorescence quantitative analysis instrument, quantitatively draws the concentration of measured matter；
5, yin and yang attribute is judged according to reference value.
Embodiment 3 test kit of the present invention compares with ELISA test kit
The test kit of the present invention and ELISA test kit detect alzheimer syndrome patients's serum 154 of clinical definite simultaneously Example, CSF sample 27 example, normal human control sera 163 example, testing result see table 1:
The test kit of table 1 present invention and ELISA test kit testing result
As it can be seen from table 1 the test kit of the present invention to the positive rate of alzheimer syndrome patients apparently higher than ELISA kit, is feminine gender to normal person's Virus monitory, it is seen that the test kit of the present invention is more more sensitive than ELISA kit, special Different, accurate.Illustrate that test kit of the present invention has higher clinical coincidence rate, can be that the detection of current alzheimer syndrome carries For more accurately, be worth reliably.
List of references
[1] Hyde SC, Emsley P, Hartsorn MJ, et al. Structure model of ATP-binding proteins associated with cystic fibrosis, multidrug resistance and bacterial transport [J]. Nature, 1990, 346(6282): 362-365.
[2] Dean M, Hamon Y, Chimini G. The human ATP-binding cassette(ABC) transporter superfamily [J]. J Lipid Res, 2001, 42(7): 1007-1017.
[3] Kaminski WE, Orso E, Diederich W, et al. Identification of a novel human sterol sensitive ATP-binding cassette transporter (ABCA7) [J]. Biochem Biophys Res Commun, 2000,273(2): 532-538.
[4] Langmann T, Manerer R, Zanhu A, et al. Real-time reverse transcription-PCR expression profiling of the complete human ATP-binding cassette transporter superfamily in various tissues [J]. Clin Chem, 2003, 49 (2), 230-238.
[5] Kim WS, Fitzgerald ML, Kang K, et al. Abca7 null mice retain normal macrophage phosphatidylcholine and cholesterol efftux activity despite alterations in adipose mass and serum cholesterol levels [J]. J Biol Chem, 2005, 280(5): 3989-3995.
[6] Kim WS, Guillemin GJ, Glaros EN, et al. Quantitation of ATP-binding cassette sub-family-A transporter gene expression in primary human brain cells [J]. Neuroreport, 2006,17(9): 891-896.
[7] Ullrich C, Pirchl M, Humpel C. Hypercholesterolemia in rats impairs the cholinergic system and lcads to memory deficits [J]. M01 Cell Neurosei, 2010, 45(4): 408-417.
[8] Kim WS, Li H, Ruberu K, Chan S, et al. Deletion of Abca7 Increases Cerebral Amyloid-βAccumulation in the J20 Mouse Model of Alzheimer’s Disease [J]. The Journal of Neuroscience, 2013,33(10): 4387-4394.
[9] Hughes TM, Lopez OL, Evans RW, et al. Markers of cholesterol transport are associated with amyloid deposition in the brain [J]. Neurobiolgy of Aging, 2014, 35(4):802-807.
[10] Holling worth P, Harold D, Sims R, et al. Common variants in ABCA7, MS4A6A/MS4A4E, ERHA1, CD33 and CD2AP are associated with Alzheimer’s disease [J]. Nat Genet, 2011, 43(5): 429-435.
[11] Liu LH, Xu J, Deng YL, et al. A complex association of ABCA7 genotypes with sporadic Alzheimer’s disease in Chinese Han population [J]. Alzheimer Dis Assoc Disord, 2014,8(2): 141-144.
[12] Liao YC, Lee WJ, Hwang JP, et al.ABCA7 gene and the risk of Alzheimer’s disease in Han Chinese in Taiwan [J]. Neurobiology of Aging, 2014, 35(10):1-7.
[13] Chung SJ, Kimb MJ, Kima YJ, et al. CR1, ABCA7, and APOE genes affect the features of cognitive impairment in Alzheimer’s disease [J]. Journal of the Neurological Sciences, 2014, 339(1-2): 91-96.
[14] Reitz C, Jun G, Nai A, et al. Variants in the ATP-binding cassette transporter (ABCA7), apolipoproteinE4, and the risk of late-onset Alzheimer disease in African Amerricans [J]. JAMA, 2013,309(14): 1483-1492.
[15] Naj AC, Jun G, Beecham GW, et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer’s disease [J]. Nat Genet, 2011,43 (5): 436-441.
[16] Lambert JC, Ibrahim-Verbaas CA, Harold D, et al. Meta-analysis of 74046 individuals identifies 11 new susceptibility loci for Alzheimer’s disease [J]. Nat Genet, 2013, 45(12): 1452-1458.
[17] Karch CM, Jeng AT, Nowotny P, et al. Expression of novel Alzheimer’s disease risk genes in control and Alzheimer’s disease brains [J]. Plos One, 2012,7(11): e50976.
[18] Engelman CD, Koscik RL, Jonaitis EM, et al. Interaction between two cholesterol metabolism genes influences memory: findings from the Wisconsin Registry for Alzheimer’s Prevention [J]. Journal of Alzheimer’s disease, 2013, 36(4): 749-757。

Claims (15)

1. alzheimer syndrome mark ABCA7 detection kit and a preparation method, its special disease is, this test kit Including PVC base plate, fluorescence pad, nitrocellulose filter, sample pad and adsorptive pads；Described sample pad, fluorescence pad, nitric acid Cellulose membrane, adsorptive pads are fixed on PVC base plate by horizontal direction；Described knot fluorescence closes has coated mouse-anti people ABCA7 on pad Monoclonal antibody 1-nanometer fluorescent microspheres complex, chicken IgY-nanometer fluorescent microspheres complex；On described nitrocellulose filter There are detection line that mouse-anti people's ABCA7 monoclonal antibody 2 constitutes and the nature controlling line that rabbit anti-chicken IgY antibody is constituted.
2. a kind of alzheimer syndrome mark ABCA7 detection kit as claimed in claim 1 and preparation method, its Special disease is, described nanometer fluorescent microspheres is the red fluorescent microsphere of aldehyde radicalization, and nano particle diameter is 100 ~ 200nm, excitation wave A length of 365nm, a length of 612 ± 5nm of transmitted wave, surface has its content of aldehyde groups to be 0.1 ~ 0.5mMol/g.
3. a kind of alzheimer syndrome mark ABCA7 detection kit as claimed in claim 1 and preparation method, its Special disease is that capture antibody is monoclonal antibody that can be specific binding with target antigen.
4. a kind of alzheimer syndrome mark ABCA7 detection kit as claimed in claim 1 and preparation method, its Special disease is that binding antibody is monoclonal antibody that can be specific binding with target antigen.
5. a kind of alzheimer syndrome mark ABCA7 detection kit as described in claim 3,4 and preparation method, Its special disease is to capture antibody and binding antibody is mouse monoclonal antibody, identifies two differences on ABCA7 protein molecular Site.
6. a kind of alzheimer syndrome mark ABCA7 detection kit as claimed in claim 1 and preparation method, its Special disease is that test kit is dry type immunofluorescence quantitative method test kit.
7. a kind of alzheimer syndrome mark ABCA7 detection kit as described in claim 1,3,4 and preparation side Method, its special disease is to use double antibody sandwich method Quick kit detection people ABCA7.
8. a kind of alzheimer syndrome mark ABCA7 detection kit as claimed in claim 1 and preparation method, its Special disease is that this test kit detection required time is short, only needs 10min from detection.
9. a kind of alzheimer syndrome mark ABCA7 detection kit as claimed in claim 1 and preparation method, its Special disease is that the method is simple to operate, and test strips, without special handling, after being directly added into sample 10min, is put into immunity by sample Reading data in quantitative fluorescence analysis instrument, optical signalling is measured and analyzes and processes, quantitatively by immunofluorescence quantitative analysis instrument Draw the concentration of measured matter.
10. a kind of alzheimer syndrome mark ABCA7 detection kit as claimed in claim 1 and preparation method, Its special disease is the method detection sensitivity height, high specificity, and accuracy is high, and nanometer fluorescent microspheres is not done by extraneous background Disturb.
11. a kind of alzheimer syndrome mark ABCA7 detection kit as claimed in claim 1 and preparation methoies, Its special disease is that the method stability is high, the cancellation that nanometer fluorescent microspheres does not causes because of sample corrosion or self decay.
12. a kind of alzheimer syndrome mark ABCA7 detection kit as claimed in claim 1 and preparation methoies, Its special disease is the method range of linearity width, and the range of linearity can reach Radix Achyranthis Bidentatae up to thousand times.
13. a kind of alzheimer syndrome mark ABCA7 detection kit as claimed in claim 1 and preparation methoies, Its special disease is that detecting sample is serum, blood plasma, whole blood, cerebrospinal fluid, urine.
14. a kind of alzheimer syndrome mark ABCA7 detection kit as claimed in claim 1 and preparation methoies, Its special disease is using alzheimer syndrome mark ABCA7 as target antigen.
15. a kind of alzheimer syndrome mark ABCA7 detection kit as claimed in claim 1 and preparation methoies, Its special disease is that clinical diagnosis disease is alzheimer syndrome.
CN201610908404.XA 2016-10-18 2016-10-18 A kind of alzheimer syndrome mark ABCA7 detection kit and preparation method Pending CN106290823A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610908404.XA CN106290823A (en) 2016-10-18 2016-10-18 A kind of alzheimer syndrome mark ABCA7 detection kit and preparation method

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610908404.XA CN106290823A (en) 2016-10-18 2016-10-18 A kind of alzheimer syndrome mark ABCA7 detection kit and preparation method

Publications (1)

Publication Number Publication Date
CN106290823A true CN106290823A (en) 2017-01-04

Family

ID=57720432

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201610908404.XA Pending CN106290823A (en) 2016-10-18 2016-10-18 A kind of alzheimer syndrome mark ABCA7 detection kit and preparation method

Country Status (1)

Country Link
CN (1) CN106290823A (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103409511A (en) * 2009-07-03 2013-11-27 加的夫大学学院咨询有限公司 Diagnosis and treatment of Alzheimer's disease
CN105807067A (en) * 2016-04-13 2016-07-27 上海凯璟生物科技有限公司 Dry-type immunofluorescence kit for detecting NCAM2 (neural cell adhesion molecules 2) of patient suffering from alzheimer's syndromes and preparation method

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103409511A (en) * 2009-07-03 2013-11-27 加的夫大学学院咨询有限公司 Diagnosis and treatment of Alzheimer's disease
CN105807067A (en) * 2016-04-13 2016-07-27 上海凯璟生物科技有限公司 Dry-type immunofluorescence kit for detecting NCAM2 (neural cell adhesion molecules 2) of patient suffering from alzheimer's syndromes and preparation method

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KANAYO SATOH等: "ATP-binding Cassette Transporter A7 (ABCA7) Loss of Function Alters Alzheimer Amyloid Processing", 《THE JOURNAL OF BIOLOGICAL CHEMISTRY》 *

Similar Documents

Publication Publication Date Title
Medrek et al. Predictive biomarkers for asthma therapy
Wüthrich et al. Prevalence of atopy and respiratory allergic diseases in the elderly SAPALDIA population
Hershkovich et al. Biochemical analysis of saliva and taste acuity evaluation in patients with burning mouth syndrome, xerostomia and/or gustatory disturbances
Berthon et al. A sputum gene expression signature predicts oral corticosteroid response in asthma
Gorska-Ciebiada et al. Adiponectin, leptin and IL-1 β in elderly diabetic patients with mild cognitive impairment
Bougea et al. Salivary alpha-synuclein as a biomarker for Parkinson’s disease: a systematic review
Rinaldi et al. Electrical impedance spectroscopy for the characterization of skin barrier in atopic dermatitis
CN105759057A (en) Dry-type immunofluorescence kit for detecting Alzheimer syndrome MS4A6A and preparation method thereof
Zhao et al. Soluble toll like receptor 2 (TLR-2) is increased in saliva of children with dental caries
Schmidt et al. Children with oligoarticular juvenile idiopathic arthritis have skewed synovial monocyte polarization pattern with functional impairment—a distinct inflammatory pattern for oligoarticular juvenile arthritis
Sarlati et al. Receptor activator of nuclear factor kappa B ligand and osteoprotegerin levels in gingival crevicular fluid
WO2013184660A1 (en) Methods for diagnosing osteoarthritis
Sørensen et al. Neuroinflammatory biomarkers in cerebrospinal fluid from 106 patients with recent-onset depression compared with 106 individually matched healthy control subjects
Liu et al. Association of leptin with disease severity and inflammation indicators in Chinese obese children with allergic rhinitis
Yadav et al. Effect of periodontal therapy on lactoferrin levels in gingival crevicular fluid
Gutgesell et al. Comparison of different activity parameters in atopic dermatitis: correlation with clinical scores
Pradeep et al. Gingival crevicular fluid and plasma levels of neuropeptide Substance‐P in periodontal health, disease and after nonsurgical therapy
Wang et al. Serum vitamin D status and circulating irisin levels in older adults with sarcopenia
Inal et al. Indices of lower airway inflammation in children monosensitized to house dust mite after nasal allergen challenge
WO2014112571A1 (en) Depression marker, assay method, depression determination method, and screening method and kit for depression medication
Nascimento et al. Differential levels of inflammatory and neuroendocrine markers in the hippocampus and anterior cingulate cortex of bipolar disorder subjects: a post-mortem study
CN106290823A (en) A kind of alzheimer syndrome mark ABCA7 detection kit and preparation method
CN105807067A (en) Dry-type immunofluorescence kit for detecting NCAM2 (neural cell adhesion molecules 2) of patient suffering from alzheimer's syndromes and preparation method
Camargo et al. Epidemiology of asthma
Nikodemova et al. Transcriptional differences between smokers and non-smokers and variance by obesity as a risk factor for human sensitivity to environmental exposures

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20170104